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Crystal Structure of the Human
High-Affinity IgE Receptor
this regard, knowledge of the three-dimensional struc-
ture of FceRI may guide the design of new molecules
and approaches to treating allergy and asthma.
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FceRI belongs to a family of antibody Fc receptorsand Cell Biology
(FcRs) that play an important role in the immune re-Northwestern University
sponse by coupling the specificity of secreted antibod-Evanston, Illinois 60208
ies to a variety of cells of the immune system (Sutton²Laboratory of Molecular Allergy and Immunology
and Gould, 1993; Metzger, 1994; Ravetch, 1994; Daeron,Harvard Medical School
1997). FcR-initiated reactions of the immune system areBoston, Massachusetts 02215
important in normal immunity, as well as in allergies,
antibody-mediated tumor recognition, and autoimmune
diseases such as arthritis. Recent experiments with
Summary transgenic mice have demonstrated that the FcRs con-
trol key steps in the immune response, including anti-
Allergic responses result from the activation of mast body-directed cellular cytotoxicity (ADCC) and inflam-
cells by the human high-affinity IgE receptor. IgE- matory cascades associated with the formation of
mediated allergic reactions may develop to a variety immune complexes (Ravetch and Clynes, 1998). Fc re-
of environmental compounds, but the initiation of a ceptors that bind IgG (FcgRI, FcgRII, and FcgRIII) medi-
response requires the binding of IgE to its high-affinity ate a variety of inflammatory reactions, regulate B cell
receptor. We have solved the X-ray crystal structure activation, and also trigger hypersensitivity through
of the antibody-binding domains of the human IgE mast cells (Oettgen et al., 1994; Dombrowicz et al.,
receptor at 2.4 AÊ resolution. The structure reveals a 1997). FceRI can also trigger antiparasitic reactions from
highly bent arrangement of immunoglobulin domains platelets and eosinophils (Gounni et al., 1994; Joseph
that form an extended convex surface of interaction et al., 1997), as well as deliver antigen into the MHC
with IgE. A prominent loop that confers specificity for class II presentation pathway in dendritic cells for the
IgE molecules extends from the receptor surface near activation of T cells (Maurer et al., 1998).
an unusual arrangement of four exposed tryptophans. The a subunit of the receptor binds IgE molecules
The crystal structure of the IgE receptor provides a with high affinity (Kd of z1029 to 10210 M) and can be
foundation for the development of new therapeutic secreted as a soluble, IgE-binding fragment by the intro-
approaches to allergy treatment. duction of a stop codon before the single C-terminal
transmembrane anchor (Blank et al., 1991). The extracel-
lular domains of the a subunit belong to the immuno-Introduction
globulin (Ig) superfamily and contain seven N-linked gly-
cosylation sites that affect the secretion and stability ofThe high-affinity IgE Fc receptor (FceRI) triggers the
the receptor (Kanellopoulos et al., 1980; LaCroix andactivation of effector cells, leading to allergic reactions
Froese, 1993; Letourneur et al., 1995), although glycosyl-and anaphylactic shock. Human FceRI exists in two
ation of the receptor is not required for IgE bindingforms, as an abg2 tetramer or an ag2 trimer. The a
(Robertson, 1993; Scarselli et al., 1993).subunit is involved in IgE binding, and the b and g sub-
We have solved the crystal structure of the IgE-bind-units are the signal transduction modules. Genetic evi-
ing domains of the FceRI a subunit. A receptor a subunitdence for a prominent role of FceRI in mediating allergic
fragment expressed in insect cells yields crystals thatreactions has been provided by various studies. Mice
diffract X-rays to a resolution of 2.4 AÊ using a high-lacking the gene for the receptor a chain are unable to
energy synchrotron source. The receptor is formed ofmount IgE-mediated anaphylaxis (Dombrowicz et al.,
two truncated Ig domains that fold into a bent two-1993), and the b subunit of FceRI has been associated
domain structure that is different from other tandem Igwith asthma in genetic studies (Shirakawa et al., 1994;
domain structures. Carbohydrate moieties are observedHill et al., 1995; Hill and Cookson, 1996; Kim et al., 1998;
at three of the seven N-linked attachment sites. The IgE-Mao et al., 1998).
binding site has been identified in the second domain ofA significant fraction of the population (z20%) is af-
the receptor and includes a prominent loop that projectsfected by allergies (Sutton and Gould, 1993), and this
from the receptor surface. The crystal structure impli-century has seen a substantial increase in asthma, which
cates nearby residues in the first domain that may benow accounts for approximately one-third of US pediat-
involved in antibody binding and suggests models forric emergency room visits (Cookson and Moffatt, 1997).
the formation of a complex with the IgE-Fc region.Since IgE binding to FceRI is an obligatory step in the
initiation of reactions to different allergens, therapeutic
Results and Discussionstrategies aimed at inhibiting IgE/FceRI interactions
could provide a single treatment for these diseases. In
Structure Determination
The extracellular domains of FceRI were expressed in
different cells (Chinese hamster ovary cells, Pichia pas-³ To whom correspondence should be addressed: (e-mail: jardetz@
tochtli.biochem.nwu.edu). toris yeast, and Sf9 and Tricoplusia ni insect cells) as
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Table 1. Crystallographic Data and Model Refinement
Data Collection and Analysis
Native Au Pt
Resolution 2.4 AÊ 3.0 AÊ 4.0 AÊ
Wavelength/energy (AÊ /keV) 1.08/11.48 1.02/12.12 1.05/11.76
Completeness, % (last shell) 96.9 (92.5) 99.9 (100.0) 96.3 (69.9)
Ave. redundancy (last shell) 3.9 (3.4) 7.6 (7.3) 6.2 (2.7)
Rmerge, % (last shell) 5.7 (22.6) 10.1 (39.8) 5.1 (7.0)
,I/sI. (last shell) 23.8 (4.5) 19.0 (3.9) 35.2 (15.9)
DF/F (resolution) Ð 0.218 (20±3 AÊ ) 0.093 (20±4 AÊ )
No. of sites Ð 1 1
Phasing power acentric/centric Ð 1.50/1.93 0.41/0.61
Rcullis acentric/centric Ð 0.66/0.70 0.94/0.97
Overall figure of merit 0.487
FOM after DM 0.673
Refinement Statistics: 500±2.4 AÊ
R factor/ No. of No. of
No. of Reflections (free) Rfree, % Atoms Waters Rmsd Bonds Rmsd Angles Ave. B
10247 (880) 24.2/27.1 1620 126 0.0077 AÊ 1.538 65.7 AÊ 2
Rmerge 5 S|Ii-,I.|/ S|I|, where Ii is the intensity of an individual reflection and ,I. is the average intensity of that reflection.
R factor 5 S|Fp|-|Fc|/ S|Fp|, where Fc is the calculated and Fp is the observed structure factor amplitude.
Phasing power 5 Fhcalc/E, where Fhcalc 5 the heavy atom structure factor amplitude and E 5 the residual lack of closure error.
Rcullis 5 S||Fph 6 Fp|2|Fhcalc|/ S|Fph 6 Fp|, where Fph is the derivative structure factor amplitude.
variable length constructs (171, 172, and 176 amino followed by manual rebuilding. The current R factor and
Rfree are 24.2% and 27.1%, respectively, for all the dataacids of the mature protein) in order to obtain protein
crystals of high quality. Glycosylation of the receptor to 2.4 AÊ . No electron density is observed for three resi-
dues at the N terminus (1±3) and two residues at the Cwas required to maintain protein solubility, and the vari-
ability of the glycosylation from the different cell lines terminus (175±176), and poor density is observed for two
loops (residues 32±35 and 70±73) that are disordered inaffected the crystallization of the receptor (S. C. G. et al.,
unpublished observations). To determine the structure, the crystal. Final statistics for the model are collected
in Table 1.several hundred crystals representing five space groups
were subjected to X-ray analysis. One construct con-
taining the first 176 amino acids of the mature receptor Overall Structure
FceRI is composed of two Ig domains, D1 and D2, eachsequence, expressed using the baculovirus system
(O'Reilly et al., 1994) in T. ni cells, produced significantly z85 residues in length, that are bent at an acute angle
relative to each other (Figure 1C). The domain arrange-better crystals than other expression constructs and cell
lines. ment generates a convex surface at the top of the recep-
tor that has been implicated in binding to the Fc regionThe 176/T. ni FceRI crystallizes in a monoclinic crystal
form (spacegroup C2) with cell dimensions 88.6 3 69.6 3 of the IgE antibody. The domains are small compared
to canonical variable and constant Ig domains, and the49.3 AÊ , a 5 g 5 908, b 5 116.78, and diffracts X-rays to
a resolution of 2.4 AÊ . A native data set was collected shorter sequence is accommodated by truncation of the
C-C9-E crossover region. Both domains D1 and D2 ofat the Stanford Synchrotron Radiation Laboratory 7-1
beamline using a Mar300 imaging plate detector. Two FceRI are composed of b strands AA9BCC9EFG (Figure
1D), differing from the previously described I-set do-derivative data sets were collected at the Dupont-North-
western-Dow undulator beamline at the Advanced Pho- mains (Harpaz and Chothia, 1994) by the absence of
strand D. The nearly antiparallel domain packing placeston Source using a MarCCD detector. The statistics for
these data are shown in Table 1. In order to maximize the A9B, CC9, and EF loops of D1 and the BC, C9E, and
FG loops of D2 near the top of the receptor. One featurethe anomalous scattering for the two derivatives, the
X-ray wavelength was set above the theoretical absorp- of the topology is a crossover of the A strand from the
ABE sheet to the CC9FG sheet (Figures 1C and 1D),tion edges of the heavy metals.
The structure of FceRI was determined by multiple forming a short segment of parallel b sheet in an other-
wise antiparallel structure. In D1 the AA9 crossover makesisomorphous replacement using gold and platinum
heavy atom derivatives with the anomalous signal from contacts in the D1D2 interface, while in the D2 domain
residues in the A strand interact with D1 (Figure 1D).both derivatives. The data collection and heavy atom
phasing statistics are shown in Table 1. The MIRAS Significant structural differences are also observed
between D1 and D2. The D1 and D2 sequences containphases were used as input to the density modification
program DM (Collaborative Computational Project, 1994), z28% identical residues and superimpose with an rms
deviation of 1.26 AÊ for the Ca atoms. The F-G strandsand the resultant electron density map was of sufficient
quality that the entire model except for two flexible loops and loop differ between the two domains (Figure 1). In
D2 these strands are longer, and the FG loop projectsand five residues at the termini could be built (Figure 1A).
The model was further improved by cycles of automated above the D2 domain surface. The C9 strands also differ
between the two domains. In D2 a series of aromaticrefinement using the program CNS (BruÈ nger et al., 1998)
Structure of the Human IgE Receptor
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Figure 1. Electron Density Maps and Overall
Structure of FceRI
(A) The 3.0 AÊ experimental electron density
map, calculated using the MIRAS phases fol-
lowed by density modification with the pro-
gram DM (Collaborative Computational Proj-
ect, 1994), is shown along with the final
refined model for FceRI. The density is con-
toured at 1.4 s for residues 147±153.
(B) Electron density for carbohydrate moie-
ties linked to N42. The |2Fo-Fc| electron den-
sity map, contoured at 1 s, was calculated
to 2.4 AÊ using combined MIRAS and model
phases (prior to inclusion of carbohydrate in
the model). Two N-acetylglucosamines and
a mannose moiety were built into the density
as shown.
(C) Ribbon diagram of FceRI showing the po-
sitions of the disulfides and the FG loop in
domain 2 (D2) that is implicated in receptor
specificity. Domain 1 (D1) is shown to the
right, and D2 is shown to the left.
(D) Topology diagram of the two FceRI do-
mains showing the hydrogen-bonding pat-
terns of the b sheet structure. A short stretch
of parallel b sheet in D1 and D2 is caused by
the cross-over of the A strand. Note that the
FG strands of D2 are longer than those of D1,
contributing to the prominence of the D2-FG
loop. Yellow residues are buried in the protein
core, red residues are at the D1D2 interface,
and green residues correspond to disulfide-
bonded cysteines.
residues (Y120 and Y131) form a hydrophobic core that clearly unique, and this variation is likely to be important
in ligand binding interactions. The FG loop of D2 inpushes the C9 strand and loop away from the C strand,
altering the local conformation of this region. The FG FceRI is oriented differently with respect to D1 residues
compared to the same region of the KIR or HGHBP,loop and C-C9 strands of D2 form part of the binding
site for IgE. changing the spatial relationships of D1D2 loops that
may be involved in ligand interactions.The tertiary packing arrangement of FceRI domains
is distinct from other tandem Ig domain structures (Fig-
ures 2A and 2B). Comparison of the FcR with other
bent two-Ig domain structures reveals a high degree The D1D2 Interface
The bent shape of the FcR produces a large interfaceof variability in the bend angles and packing surfaces
between domains. A subset of representative structures between the D1D2 domains that buries 1280 AÊ 2 of acces-
sible surface area of 28 D1D2 residues (Figure 3A). Thereis shown in Figure 2, including FceRI, the natural killer
cell inhibitory receptor, KIR (Fan et al., 1997), the human are 11 residues from the D1 domain (12±18, 20, and
84±86) and 17 residues from the D2 domain that aregrowth hormone receptor, HGHBP (de Vos et al., 1992),
the interleukin-1 receptor, IL1R (Vigers et al., 1997), and buried at the interface (87±93, 95, 104, 106, 108, 110±
111, 161, and 163±165). Of these 28 residues, 8 arethe insect defense protein hemolin (Su et al., 1998). The
proteins are oriented relative to D2 of FceRI. The ABE completely conserved in all human FcgR and FceR se-
quences (Figure 3B, residues 13, 87, 88, 90, 91, 106,half of each domain is colored yellow and the A9CC9FG
half is colored blue, with light colors for domains corre- 108, and 110). These conserved residues are colored
yellow in Figure 3A, and they form a significant fraction ofsponding to FceRI D1 and dark colors for domains corre-
sponding to FceRI D2. FceRI and hemolin structures one side of the buried interface, suggesting that related
FcRs would have a similar acute packing of the D1D2have the most acute angles relating two sequential Ig
domains. The top view of these domains shows that the domains as observed in FceRI.
However, 20 residues that form the D1D2 interfaceorientations of the hemolin and FcR domains are more
closely related, but between this selected subset of pro- differ in other FcRs, and these differences could alter the
relative orientations of the two domains. The conservedteins there is significant variability in the relative orienta-
tions of tandem Ig domain structures. The bend angle tryptophan at position 110 packs against phenylalanine
17 in FceRI. In other FcRs, F17 is a leucine (Figure 3B),between domains and domain packing interfaces are
Cell
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Figure 2. FceRI Has a Novel Tertiary Arrangement of Tandem Ig Domains
(A) Side view of different tandem Ig domain arrangements in FceRI, KIR, HGHBP, IL1-R, and hemolin. These five proteins were selected to
demonstrate the variety of two sequential Ig domain arrangements with varying bend angles between domains. The five are oriented relative
to FceRI by the second C-terminal domain under comparison. The b sheets of the Ig domains are colored to clearly indicate the two faces
of the domains. For the first of the two domains, the ABE sheet is colored light yellow, while the A9CC9FG sheet is colored light blue. For D2
the ABE sheet is colored dark yellow, and the A9CC9FG sheet is colored dark blue. This coloring is conserved in the four other proteins for
the corresponding sheets, allowing straightforward comparison despite different sheet structures in the different Ig domains being compared.
This comparison shows the variety of domain±domain angles found in tandem Ig domains.
(B) Top view of the five proteins oriented looking down the central axis of the C-terminal Ig domain. Note the variation in packing between
bent Ig domains in these proteins, which includes rotational variation around the D2 axis, as well as variation in the D1 surface used to form
the domain:domain interface. FceRI packing is distinct from all of these arrangements but is most similar to the domain packing arrangement
found in hemolin.
which may alter the packing of the two domains. Arg- to this region of the FcR, this surface could be a site of
interaction with the extracellular regions of the b or g15 forms a hydrogen bond with the carbonyl of L90 and
contacts L89, F84, and L165. In other human FcRs, R15 subunits of the receptor. It has been suggested that
interactions between the FcgRI and FcgRIIIA a and gis either serine or asparagine, changing the volume and
charge at the center of the D1D2 interaction. Since the subunits increase the binding affinity of the receptor for
IgG (Miller et al., 1996). The 5±7 extracellular amino acidsinteractions of the FcR with antibody are near the D1D2
interface, alterations in residues at the interface might of the g chain could potentially interact with the D1D2
cleft and affect the affinity of the receptor for antibody.influence receptor specificity. Other residues that are
variable among the FcR sequences in the region of the Recent binding studies with soluble FceRI and IgE have
also demonstrated a 10-fold lower affinity than had pre-D1D2 interface could also perturb the D1D2 interactions
(Figures 1D and 3B). viously been determined in cell-binding assays (Cook
et al., 1997).The bent FcR structure generates a cleft between the
two domains that is near the transmembrane anchor at
the C terminus of D2 (Figure 1C). This cleft is located Carbohydrate Attachment Sites
FceRI is the most highly glycosylated protein structurefar from the IgE-binding site identified by mutagenesis
studies. Although there is no known function attributed solved by X-ray crystallography to date, having seven
Structure of the Human IgE Receptor
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Figure 3. Sequence and Carbohydrate At-
tachment Site Variability in Related FcRs
(A) Amino acid interactions at the D1-D2 inter-
face. Residues buried at the D1D2 interface
are shown with absolutely conserved resi-
dues in yellow and others in white. The inter-
action of D1 with D2 buries 1280 AÊ 2 of surface
area and involves 28 residues in the two do-
mains.
(B) Sequence alignments of human Fc recep-
tors. The sequence alignment indicates the
positions of predicted carbohydrate attach-
ment sites (highlighted in yellow for the hu-
man sequences). The secondary structure of
the two domains is also indicated with labeled
bars above those residues that form b sheets
in FceRI. Below the sequences, carbohydrate
attachment sites found in 17 different FcR
sequences are indicated with plus signs. This
analysis is based on the seven human recep-
tors shown and the nonhuman receptors in
Table 2. Also shown below each residue posi-
tion is the number of different amino acids
found in the human IgG and IgE receptor
alignment. The most variable amino acid po-
sitions (different in more than 4 of 7 se-
quences) are highlighted.
(C) Surface representation of FceRI showing
all of the seven carbohydrate attachment
sites (blue regions of surface) and the carbo-
hydrate structures for which interpretable
electron density has been observed at resi-
dues 21, 42, and 166.
N-linked glycosylation sites in 176 amino acid residues. The other carbohydrate sites are indicated on the FceRI
surface as blue regions of the surface. No interpretableThe intact receptor on mast cells is approximately 40%
carbohydrate by weight (Kanellopoulos et al., 1980; La- density is observed for these glycosylation sites.
Many of the related FcRs are also highly glycosylatedCroix and Froese, 1993), with a heterogeneous molecu-
lar weight on SDS-PAGE gels of z50 kDa. The receptor proteins, and the glycosylation sites vary between re-
ceptors. The rat and mouse FceRIs each have six poten-expressed in insect cells has a molecular weight of z34
kDa as observed using SDS-PAGE, but based on typical tial N-linked glycosylation sites, but the rat receptor has
only two sites and the mouse receptor only one site ininsect cell glycosylation structures (-GlcNAc2-Man3-
GlcNAc), it could be expected to have a molecular common with the human receptor. Comparison of 17
human and animal FcR sequences identifies 25 differentweight of z27.5 kDa, or approximately 30% carbohy-
drate by weight. While the presence of carbohydrate potential N-linked carbohydrate attachment sites in re-
lated FcRs (Figure 3B). The 25 sites are distributedat these seven sites is not required for binding to IgE
(Robertson, 1993; Scarselli et al., 1993; Letourneur et evenly between D1 and D2, with 14 sites in D1 and 11
sites in D2. Five of these sites are relatively well con-al., 1995), mutation of these sites or treatment of FcR-
expressing cells with tunicamycin leads to the aggrega- served sites in all FcRs (found in .9/17 sequences ana-
lyzed), corresponding to residues 35, 42, 61, 135, andtion of the receptor during biosynthesis.
In the FceRI crystal structure, carbohydrate density 142 (Figure 3B). The distribution of all of the sites on
the surface of FceRI is shown in Figure 4A (gray Cais observed at three of the seven predicted glycosylation
sites (Figure 3C, residues 21, 42, and 166). For two of positions). These sites cover a significant fraction of the
FceRI surface on both major faces of D1 and D2, placingthese sites, Asp-42 and Asp-166, three sugar moieties
were built. The carbohydrate at position 42 extends up limitations on the FcR surface available for interactions
with antibody.toward the top of the FceRI structure, covering residues
F60, S63, and V83. The carbohydrate attached to posi-
tion 166 projects away from the protein surface, poten- The Receptor-Binding Site for IgE
A number of mutagenesis studies have been carried outtially as a result of crystal contacts and the modification
of the 3 and 6 positions of the first GlcNac residue. to elucidate the regions of FceRI that are critical for the
Cell
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Figure 4. Identification of the FceRI-Binding
Site for IgE
(A) Residues of FceRI implicated in binding
IgE, shown in three orientations of the recep-
tor (side and top views). Residues that have
been identified by mutagenesis studies in
forming the binding site for the IgE-Fc are
shown in yellow. Two residues that affect
FceRI binding to a mutant IgE-Fc (R334S) are
shown in magenta. Carbohydrate attachment
sites for all of the human and nonhuman re-
ceptors in Table 2 are colored gray in the Ca
track. Note that the carbohydrate sites cover
a substantial portion of the FcR surface, but
they do not impinge on the binding site region
identified by mutagenesis.
(B) A surface representation of the IgE recep-
tor showing the surface exposure of aromatic
residues in blue. The patch corresponding to
the four tryptophans is indicated. Aromatic
residues that form part of the predicted IgE-
binding site are also evident in the D2 C-C9
region.
interaction with IgE molecules (Hulett et al., 1993, 1994, of IgE and five different monoclonal antibodies, sug-
gesting that residue differences in these segments may1995; Mallamaci et al., 1993; Cook et al., 1997). These
experiments have demonstrated an important role for affect the folding of hybrid molecules.
FceRI residues that have been implicated in IgE bind-amino acids in the D2 domain of the receptor, although
some regions of D1 are also likely to be involved in IgE ing include residues in the D2 C strand (115, 117, 118,
and 120±123), the C9-E loop (129 and 131), the F strandbinding. Current evidence that D1 plays a role in IgE
binding includes the deletion of D1 (Robertson, 1993; (149 and 153), the FG loop (155), and the G strand (159)
(Hulett et al., 1994, 1995; Cook et al., 1997). In addition,Scarselli et al., 1993) or substitution with a homologous
IgG receptor (Hulett et al., 1994). These experiments do residues 87 (at the D1D2 interface) and 128 (in the C9-E
loop) are likely to be part of the IgE interaction site,not determine conclusively whether D1 interacts directly
with the IgE or whether D1 indirectly alters the structure since mutation of these residues influences receptor
binding to the IgE point mutant R334A (Cook et al.,of D2 and subsequent interactions with IgE. The substi-
tution or elimination of residues at the D1D2 interface 1997). Of these 15 residues, 6 are buried in the protein
core, and substitution may lead to indirect structural(Figure 3B) could potentially influence D2 interactions
with antibody Fc regions. There are a number of regions changes that affect IgE binding (115, 118, 120, 131, 149,
and 155). Three of the residues are either partially buriedof D1 that have been excluded from determinants of the
specificity of the receptor for IgE, since these FceRI or glycine and substitution may affect the conformation
of the local residues (122, 129, and 153). The remainingsegments can be substituted by the corresponding resi-
dues in the FcgRIIIA protein (Mallamaci et al., 1993), residues (87, 117, 121, 123, 128, and 159) are all exposed
amino acids at the FceRI surface. A synthetic peptideincluding residues 25±38, 43±54, 67±79, and 77±86. Sub-
stitution of residues 10±21 or 55±67 disrupts the binding containing residues 119±129 has been demonstrated to
Structure of the Human IgE Receptor
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Figure 5. Implications for FceRI Specificity and Its Interaction with IgE
(A) Four surface-exposed tryptophans at the top of the D2 domain that are implicated in IgE binding.
(B) Residues in the D2-FG loop and D1-E strand that are highly variable in human FcR sequences. The residues in the D2-FG loop have been
directly implicated in IgE binding (see text). The residues in the D1-E strand and the D1-A9B loop are located near the top of the D2 domain
and could form part of an extended IgE-binding surface between the two domains. Note that the carbohydrate attachment sites shown in
Figure 4A are consistent with a continuous Fc-binding surface spanning the two domains involving these D1 loop regions.
(C) Juxtaposition of FceRI with a model for the intact IgE antibody structure. The IgE model is derived from the intact IgG1 antibody (Harris
et al., 1998). The insertion of the Ce2 domains in the IgE molecule is indicated by dotted lines. The FceRI a chain is shown relative to the
mast cell membrane near the top of the Ce3 domains that bind to the receptor.
block IgE binding to the receptor, with a Kd of z3 mM probably forms a contact surface for a complementary
interaction with the IgE. Trp-87 has already been impli-(McDonnell et al., 1996, 1997). The implicated residues
(Figure 4A) form a contiguous surface extending from cated by mutagenesis studies, and Trp-156 is promi-
nently displayed at the top of the FG loop. Trp-156 is athe back side of the D2 domain to the top region near
the D1D2 interface. Four of the residues are conserved glycine in all IgG-FcRs (Figure 3B), and grafting of FceRI
FG-loop (residues 154±161) to the FcgRII IgG-FcR con-in all human FcRs (87, 118, 149, and 153) and may define
a set of common interactions between all FcR receptors fers IgE binding.
and their target Ig molecules.
The region of the D2 domain defined by mutagenesis Implications for the Binding Specificity
of Fc Receptorsalso borders on a number of surface-accessible aro-
matic residues, including four prominent tryptophans at Since carbohydrate would be expected to disrupt any
closely packed protein:protein interface, it is interestingthe top of the FcR molecule, residues 87, 110, 113, and
156. Figure 4B shows a surface representation of all of to compare the known carbohydrate sites with the pro-
posed IgE-binding site on the receptor surface. All ofthe exposed aromatic groups of the FcR, outlining the
tryptophan ridge and residues in D2 near the CC9-E the carbohydrate attachment sites for 17 related FcRs
are shown in Figure 4A, demonstrating that the N-linkedregion that has been identified by mutagenesis studies.
The four tryptophans are shown in Figure 5A, forming carbohydrate sites delineate a boundary around the pro-
posed IgE-binding site. This is consistent with relateda flat, hydrophobic ridge that neighbors the D2 FG loop.
This unusual arrangement of four exposed tryptophans FcRs sharing a common binding surface for antibody
Cell
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molecules. Studies of the FcgRII specificity for IgG have receptor has been extensively studied by mutagenesis,
implicating amino acids in the third constant domainimplicated residues in the same region of the receptor,
(Ce3) of the IgE (Nissim et al., 1991; Basu et al., 1993;including residues 113±116, 129, 131, 133, 134, 155, 156,
Presta et al., 1994; Henry et al., 1997). The structure ofand 159±161 (Hulett et al., 1994, 1995). In addition, many
the IgE-Fc region has not been experimentally deter-domain-swap experiments have demonstrated that two
mined but is homologous to the IgG-Fc, for which aof the related IgG-FcRs can form functional hybrid mole-
number of crystal structures are available. The IgG-Fc-cules with FceRI (Mallamaci et al., 1993; Hulett et al.,
binding site for the FcgRI and FcgRII receptors has been1995), suggesting that these receptors share a common
mapped to a similar, although smaller, surface that pri-binding surface with their respective antibody ligands.
marily includes residues in the hinge region before theThe top of the FcR structure is devoid of carbohydrate
Cg2 domain (Duncan et al., 1988; Jefferis et al., 1990;attachment sites in the region of D2 that has been impli-
Canfield and Morrison, 1991; Lund et al., 1991).cated in direct interactions with Ig molecules. The neigh-
The antibody Fc region is a homodimeric structureboring surface of the D1 domain, including loops A9B
that is significantly larger than the Fc receptor (Figureand EF, is also devoid of carbohydrate and could form
5C). The observed 1:1 stoichiometry between receptorpart of an extended antibody-binding site across the
and antibody indicates that the two-fold symmetry ofD1D2 interface. If these D1 loops are important in de-
the Fc region does not lead to the binding of two FcRs,termining the specificity and affinity of the FcR:antibody
even with isolated molecules in solution. The large andinteraction, one might observe sequence variability be-
convex nature of the FcR-binding surface could spantween high- and low-affinity IgG receptors and the IgE
two antibody domains (Cg2 in IgG and Ce3 in IgE) andreceptor. This variability in the human IgG and IgE recep-
induce a conformational change in the Fc that wouldtors is shown in Figure 3B. For residues 3±173, there
prevent the binding of a second FcR to the same anti-are 73 amino acid differences that are unique to FceRI
body. The FcR structure could also form an asymmetriccompared to the IgG receptors, and there are five re-
complex with the antibody that sterically blocks thegions that stand out with clusters of sequence variability:
binding of a second FcR, perhaps using the protrudingresidues 27±30, 47±49, 54±59, 94±98, and 155±159. Resi-
FG loop to block symmetric interactions with the Fcdues 155±159 (the FG loop) are highly variable and at
hinge region.least partially determine the specificity of FcR interac-
The FcRs vary in their level of glycosylation. In FceRIastions.
the number of glycosylation sites (6±7) is maintained,
Previous experiments have shown that residues 27±30
but the position of these sites varies. In the human FcRs,
and 47±49 are not critical for FcR specificity (Mallamaci
the number of glycosylation sites shows some correla-
et al., 1993), and the presence of glycosylation sites tion with binding affinity (Table 2). The high-affinity FcRs,
within these segments in related FcRs (Figure 3B) sup- which can bind Ig prior to the binding of antigen, typically
ports the suggestion that these regions are not part of have 5±7 potential glycosylation sites. Low-affinity
the FcR:antibody interaction. Residues 94±98 are found FcRs, which bind Ig±antigen aggregates, have as few
in the A9 strand near the D1D2 cleft and therefore are as two sites. Since FcR activation requires cross-linking
not likely to interact with antibody directly, but these of receptors, glycosylation might prevent the aggrega-
residues might influence interactions indirectly by alter- tion of large antibodies at the cell surface bound by
ing the D1D2 packing interface. high-affinity FcRs. Lipid/water interfaces can enhance
The remaining group of highly variable residues (54± the crystallization of proteins (Hemming et al., 1995), and
59) are in the D1 E strand (Figure 5B), near the FceRI- the potentially high local concentrations of membrane-
binding site. Residues 54±59 could form a D1 surface bound Ig might lead to FcR activation in the absence
of interaction with the Ig-Fc domains, extending the of antigen. The low-affinity IgG receptors interact with
binding site across both FcR domains. Since exchange antibody±antigen aggregates that can simultaneously
of FceRI residues 55±67 with residues from the FcgRIIIA bind and activate multiple FcRs. In these receptors, gly-
receptor may disrupt the folding of the protein (Malla- cosylation may not be quite as important, since interac-
maci et al., 1993), targeted point mutations may be re- tion with the antibody could occur after the binding of
quired to test the importance of residues in the D1-E antigen.
strand. The neighboring D1 A9B loop (residues 18±21) There may be other roles for the FcR glycosylation,
could also form part of an extended surface of interac- since the nonhuman FcRs (Table 2) do not show an
tion with the antibody. obvious correlation of the number of carbohydrate sites
and FcR affinity. Glycosylation might be important in
FcR signaling by orienting receptor:antibody complexes
Conclusions into functional signaling complexes (i.e., by preventing
The activation of Fc receptor bearing cells requires antigen-cross-linked complexes from forming nonfunc-
cross-linking of the receptors, which leads to the activa- tional aggregates). It is known that activation through
tion of intracellular kinase cascades analogous to those the IgE receptor is sensitive to geometrical constraints
in B and T cells (Metzger, 1992; Daeron, 1997). For both imposed by antigen cross-linkers, although the nature
high- and low-affinity receptors (the FceRI and FcgRIII), of these physical constraints is poorly understood. The
a stoichiometry of 1:1 is observed between the receptor recent crystal structure determination of an erythropoei-
and the Ig-Fc region (Kanellopoulos et al., 1980; Ghir- tin±receptor complex suggests that the orientation of
lando et al., 1995; Keown et al., 1997), consistent with ligand-mediated dimerization of cell-surface receptors
a requirement for antigen to cause receptor aggregation may be important in efficient signal transduction (Syed
et al., 1998).and activation. The binding site on the IgE-Fc for its
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transfection system (Pharmingen). Supernatants of transfected Sf9
Table 2. FcR Glycosylation Sites and Ig Binding Affinity cells were amplified once in TNM-FH medium (Pharmingen), fol-
lowed by a second amplification in serum-free medium (SF-900,No. of CHO
GIBCO). For each virus stock used in protein production, the optimalFcR Sites (Total) Affinity
amount of virus and harvest time postinfection was determined by
Human small scale tests in 50 ml shaker flasks.
T. ni (Hi-5) cells grown in shaker or spinner flasks were usedFceRI 7 High (1029±10210M)
for protein production and purification. Typical yields for proteinFcgRIA (CD64) 5 (7) High (3 domains, 1028±1029M)
expression were 2±12 mg/l of infected cells 2±4 days after infection.FcgRIB (CD64) 5 (7) High (3 domains, 1028±1029M)
Supernatants from 1.5±5 l of Hi-5 cells were collected, filtered
FcgRIIA (CD32) 2 (3) Low (1026M) through 0.2 micron filters, and loaded onto a Mab15-1 (Sechi et al.,
FcgRIIB (CD32) 3 Low (1026M) 1996) monoclonal antibody column. Supernatants were recirculated
FcgRIIC (CD32) 3 (4) Low (1026M) over the column at least twice, followed by buffer washes (z300
FcgRIIIA (CD16) 5 (6 in variant) Low (1026M) ml, 100 mM Na, KPO4 [pH 7]), until the absorbance at 280 nm of the
eluant returned to zero. The protein was eluted by two urea washes:Mouse
100 ml of 5 M urea in 100 mM phosphate (pH 7.0), then 100 ml of
FceRI 6 High (1029±10210M) 7 M urea in 100 mM phosphate (pH 7.0), followed by extensive
FcgRI 4 (5) High (3 domains, 1027±1028M) regeneration with 100 mM Na, KPO4 (pH 7.0). The urea eluants were
FcgRIIb 4 (5) Low (1026M) pooled, concentrated to z25±40 ml with an Amicon stirring concen-
FcgRIIIa 4 Low (1026M) trator, and dialyzed four times against 2 l of 50 mM Tris (pH 7.5).
The purity was verified by SDS-PAGE and protein stored at 48C forRat
crystallization in the presence of 0.05% sodium azide. Final yield
FceRI 7 High (1029±10210M) of the protein was z50% based on an absorption coefficient of 2.6
FcgRII 6 (7 total) Low (mg21)(cm2) for the purified protein and the total protein estimated
FcgRIII 5 Low using ELISA assays with the initial cell supernatants.
Other
FcR ELISA Assay
FcgRII An inhibition-ELISA assay was used to quantitate receptor expres-
(guinea pig) 5 (6) Low sion. The binding of Mab15-1 antibody to plate-bound FceRI is moni-
FcgRIII (pig) 3 Low tored using a goat anti-mouse-alkaline phosphatase antibody
FcgRII (bovine) 6 Low (Sigma, A-2429). Unknown samples compete for antibody binding
and are compared to a standard curve. Fifty microliters of purifiedComparison of the number of predicted glycosylation sites and the
FceRI was incubated in microtiter plates o/n at 48C at a concentrationaffinity of different FcRs for antibody. The number of glycosylation
of 1 mg/ml in phosphate-buffered saline. Plates were rinsed withsites in the domains corresponding to the extracellular fragment of
wash buffer containing 20 mM HEPES 7.5, 100 mM NaCl, 0.1%the human FceRI are shown along with the total number of glycosyla-
Tween-20, and blocked with HEPES/NaCl buffer with 1% Carnationtion sites in parentheses. The affinities quoted are taken from Ra-
dry milk. Standard inhibitor samples ranging from 0.1±50 mg/ml ofvetch and Clynes (1998) and Ravetch and Kinet (1991).
FceRI in two-fold dilution series were incubated with Mab15-1 (0.1
mg/ml final concentration) and added in duplicate to wells coated
with FceRI. Standard controls included wells without o/n incubation
with FceRI, and addition of Mab15-1 without inhibiting FceRI. Sec-Although the receptor-binding site for IgE is overall
ondary antibody in a 1:5000 dilution was incubated after washing
broad and convex in shape, there are regions on the for 1±2 hr at room temperature. Plates were washed and developed
surface of the receptor that are candidate targets for using the AP reagent p-nitrophenyl phosphate (PNPP, Sigma 104±
small molecule inhibitors. Crystal packing interactions 105). Microplates were read using a Molecular Devices SpectraMax
Plus reader at 405 nm.with the four exposed tryptophans show that small hy-
drophobic groups can interact with the adjacent indole
Crystallization and Data Collectionmoeities at the top of the IgE-binding site. Other grooves
Purified FceRIa was concentrated to a final concentration of 20 mg/or pockets on the FcR surface might also bind potential
ml in 20 mM Tris (pH 7.5). Crystallization was carried out using the
small molecule inhibitors, such as the C-strand region hanging drop method, with a precipitant composed of 100 mM Tris
of D2 or the D1D2 cleft. (pH 8.5), 200 mM NaOAc, and 18%±24% PEG 4000. Crystals were
obtained in 2±10 days amid significant amounts of protein precipi-
tate. At lower PEG concentrations a different crystal form is ob-Experimental Procedures
served. The crystals used in the structure determination typically
grow as clusters of 3±20 crystals that can be separated manually.Expression and Purification of the Human High-Affinity
IgE Receptor The crystals belong to the monoclinic space group C2, with cell
dimensions 88.6 3 69.6 3 49.3 AÊ , a 5 g 5 908, b 5 116.78, with oneThe human FceRIa protein was expressed in insect cells using the
baculovirus expression system. The construction and expression receptor molecule per asymmetric unit.
Crystals were harvested into harvest buffer containing 35% PEGof this and other vectors for the FceRIa will be described in detail
elsewhere (S. C. G. et al., unpublished data). Briefly, DNA including 4000, 100 mM Tris (pH 8.5). For data collection, crystals were
mounted in nylon loops (Hampton-Research) and rapidly cooled inthe wild-type receptor signal sequence and first 176 amino acids
of the mature receptor a chain were cloned into the pVL1392 bacu- liquid nitrogen after a short (z30 s) soak in harvest buffer supple-
mented with 14% glycerol. Heavy atom soaks with K2PtBr4 andlovirus transfer vector (Pharmingen). An EcoRI-HindIII fragment from
plasmid EdpC20 (Blank et al., 1991) containing the receptor signal K3AuCl3 were done in harvest buffer with 5 mM Pt for 48 hr and 1
mM Au for 18 days. Data were collected at the Stanford Synchrotronsequence and residues 1±172 was ligated to two oligonucleotides
coding for the receptor residues 172±176 and two stop codons. The Radiation Laboratories (SSRL) 7-1 beamline and at the Dupont-
Northwestern-Dow undulator beamline at the Advanced Photonsynthetic oligonucleotides (59-agctCCGCGT GAGAAGTAAT AAG-39
and 59-gatcCTTATT ACTTCTCACG CGG-39) have HindIII and BamHI Source at Argonne National Laboratories (Table 1). For the Pt and
Au data sets, the wavelength was chosen to be 200 eV above theoverhangs when annealed together, allowing the subcloning of the
1±176 construct in EcoRI-BamHI cleaved pVL1392. The resultant absorption edge of the metal, in order to maximize the anomalous
signal for each heavy atom. Heavy atom data were collected usingconstruct was verified by DNA sequencing. Recombinant baculovi-
rus expressing the receptor was generated using the Baculogold reverse beam protocols to optimize the anomalous diffraction signal.
Cell
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Diffraction data were collected with a Mar300 Image plate (SSRL) Cookson, W.O., and Moffatt, M.F. (1997). Asthma: an epidemic in
the absence of infection? Science 275, 41±42.or a MarCCD detector (DND-CAT), and integrated and scaled with
DENZO/SCALEPACK (Otwinowski and Minor, 1997). The CCP4 suite Daeron, M. (1997). Fc receptor biology. Annu. Rev. Immunol. 15,
of programs (Collaborative Computational Project, 1994) was used 203±234.
for further processing and identification of heavy atom sites. de Vos, A.M., Ultsch, M., and Kossiakoff, A.A. (1992). Human growth
hormone and extracellular domain of its receptor: crystal structure
MIR Phasing and Structure Refinement of the complex. Science 255, 306±312.
Heavy atom positions were identified from peaks in the anomalous Dombrowicz, D., Flamand, V., Brigman, K.K., Koller, B.H., and Kinet,
and isomorphous difference patterson maps. Heavy atom positions J.P. (1993). Abolition of anaphylaxis by targeted disruption of the
were refined and phases calculated with the program MLPHARE, high affinity immunoglobulin E receptor alpha chain gene. Cell 75,
followed by solvent flattening and density modification with the 969±976.
program DM. The subsequent model was refined using the CNS
Dombrowicz, D., Flamand, V., Miyajima, I., Ravetch, J.V., Galli, S.J.,
program (BruÈ nger et al., 1998) with the combined maximum likeli- and Kinet, J.P. (1997). Absence of FceRIa chain results in upregula-
hood and experimental phase target (MLHL). The model was refined tion of FcgRIII-dependent mast cell degranulation and anaphylaxis.
against all data from 500 to 2.4 AÊ using a bulk solvent model. Refine- Evidence of competition between FceRI and FcgRIII for limiting
ment steps were accepted only when they produced a decrease in amounts of FcR beta and gamma chains. J. Clin. Invest. 99, 915±925.
the Rfree. Since refinement of restrained temperature factors for every
Duncan, A.R., Woof, J.M., Partridge, L.J., Burton, D.R., and Winter,atom did not lead to a decrease in Rfree, only two thermal parameters
G. (1988). Localization of the binding site for the human high-affinityper amino acid were allowed. The model contains one residue (Trp-
Fc receptor on IgG. Nature 332, 563±564.156) in the disallowed region of the Ramachandran diagram. Current
Fan, Q.R., Mosyak, L., Winter, C.C., Wagtmann, N., Long, E.O., andrefinement statistics are listed in Table 1.
Wiley, D.C. (1997). Structure of the inhibitory receptor for humanFigures were generated with the programs O (Jones et al., 1991),
natural killer cells resembles haematopoietic receptors. Nature 389,MOLSCRIPT (Kraulis, 1991), Raster3d (Merritt and Bacon, 1997),
96±100.and GRASP (Nicholls et al., 1991).
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